Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
EphB6-null mutation results in compromised T cell function
Hongyu Luo, … , Johanne Tremblay, Jiangping Wu
Hongyu Luo, … , Johanne Tremblay, Jiangping Wu
Published December 15, 2004
Citation Information: J Clin Invest. 2004;114(12):1762-1773. https://doi.org/10.1172/JCI21846.
View: Text | PDF
Article Immunology

EphB6-null mutation results in compromised T cell function

  • Text
  • PDF
Abstract

So far, there is very limited knowledge about the role of Eph kinases, the largest family of receptor tyrosine kinases, in the immune system. Here, using EphB6–/– mice, we demonstrated that in vitro and in vivo T cell responses such as lymphokine secretion, proliferation, and the development of delayed-type skin hypersensitivity and experimental autoimmune encephalitis in EphB6–/– mice were compromised. On the other hand, humoral immune responses, such as serum levels of different Ig isotypes and IgG response to tetanus toxoid, were normal in these mice. Mechanistically, we showed that EphB6 migrated to the aggregated TCRs and rafts after TCR activation. Further downstream, in the absence of EphB6, ZAP-70 activation, LAT phosphorylation, the association of PLCγ1 with SLP-76, and p44/42 MAPK activation were diminished. Thus, we have shown that EphB6 is pivotal in T cell function.

Authors

Hongyu Luo, Guang Yu, Johanne Tremblay, Jiangping Wu

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
EphB6 cocapped with TCR and rafts upon TCR stimulation. Capping of thymo...
EphB6 cocapped with TCR and rafts upon TCR stimulation. Capping of thymocyte TCR (A–C; stained with biotinylated anti-CD3 and biotinylated anti-CD4 followed by streptavidin–Alexa Fluor 594 in red), EphB6 (A, B, and D; stained with goat anti–mouse EphB6 followed by Alexa Fluor 488–conjugated donkey anti-goat IgG in green), and rafts (D; stained by Alexa Fluor 594–conjugated cholera toxin in red) was assessed by confocal microscopy. Thymocyte surface CD45 (C; stained with FITC-conjugated anti-CD45) was used as a control. “Resting” indicates thymocytes without stimulation; “activated” indicates thymocytes cross-linked with anti-CD3 and anti-CD4 at 37–C for 2 minutes. All experiments were performed at least 3 times and were reproducible; representative results are shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts